Tech Company Financing Transactions

Basilea Pharmaceutica Funding Round

Carb-X joined a $6 million capital raise for Basilea Pharmaceutica. The round was announced on 4/9/2026.

Transaction Overview

Announced On
4/9/2026
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Undisclosed
Investors

Carb-X (Richard Alm)

Proceeds Purpose
The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea's novel antibiotic BAL2420 (LptA inhibitor)1 and related activities.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Hegenheimermattweg 167b
Allschwil, 4123
Switzerland
Email Address
Overview
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 190 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Profile
Basilea Pharmaceutica LinkedIn Company Profile
Social Media
Basilea Pharmaceutica Company Twitter Account
Company News
Basilea Pharmaceutica News
Facebook
Basilea Pharmaceutica on Facebook
YouTube
Basilea Pharmaceutica on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Veitch
  David Veitch LinkedIn Profile  David Veitch Twitter Account  David Veitch News  David Veitch on Facebook
Chief Financial Officer
Adesh Kaul
  Adesh Kaul LinkedIn Profile  Adesh Kaul Twitter Account  Adesh Kaul News  Adesh Kaul on Facebook
Chief Medical Officer
Marc Engelhardt
  Marc Engelhardt LinkedIn Profile  Marc Engelhardt Twitter Account  Marc Engelhardt News  Marc Engelhardt on Facebook
Chief Scientific Officer
Laurenz Kellenberger
  Laurenz Kellenberger LinkedIn Profile  Laurenz Kellenberger Twitter Account  Laurenz Kellenberger News  Laurenz Kellenberger on Facebook
Chief Technical Officer
Gerrit Hauck
  Gerrit Hauck LinkedIn Profile  Gerrit Hauck Twitter Account  Gerrit Hauck News  Gerrit Hauck on Facebook
VP - General Counsel
Damian Heller
  Damian Heller LinkedIn Profile  Damian Heller Twitter Account  Damian Heller News  Damian Heller on Facebook
VP - Human Resources
Ursula Eberhardt
  Ursula Eberhardt LinkedIn Profile  Ursula Eberhardt Twitter Account  Ursula Eberhardt News  Ursula Eberhardt on Facebook
VP - Regulatory Affairs
Peter Bielmeier
  Peter Bielmeier LinkedIn Profile  Peter Bielmeier Twitter Account  Peter Bielmeier News  Peter Bielmeier on Facebook
VP - Regulatory Affairs
Mark Jones
  Mark Jones LinkedIn Profile  Mark Jones Twitter Account  Mark Jones News  Mark Jones on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/9/2026: TeiaCare venture capital transaction
Next: 4/9/2026: CertifID venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary